Actinium-225-PSMA radioligand therapy of metastatic castration-resistant prostate cancer (WARMTH Act): a multicentre, retrospective study

Actinium-225-PSMA radioligand therapy of metastatic castration-resistant prostate cancer (WARMTH Act): a multicentre, retrospective study

This is a large retrospective international of 225-Ac PSMA conducted in 488 men with pretreated mCRPC. Median OS was 15.5 months with a median PFS of 7.9 months: xerostomia was the most frequent side effect (68%). The authors conclude that there is a substantial anti-tumor effect and this therapy represents a viable option in these patients.

READ THE ARTICLE – https://www.thelancet.com/journals/lanonc/article/PIIS1470-2045(23)00638-1/fulltext

Share this post